IBRX

Immunitybio Stock Analysis

AI Rating

Great
  • Quality6/10
  • Growth↑ 6/10
  • Momentum↑ 9/10
Immunitybio sales and earnings growth
IBRX Growth
Good
  • Revenue Y/Y↑ 668.31%
  • EPS Y/Y↑ 35.59%
  • FCF Y/Y↑ 22.34%
Immunitybio gross and profit margin trends
IBRX Profitability
Good
  • Gross margin ↑ 99.30%
  • EPS margin↓ -310.20%
  • ROIC↓ -21.40%
Immunitybio net debt vs free cash flow
IBRX Risk
Great
  • Debt / Equity↓ -1.7
  • Debt / FCF↓ 2.4
  • Interest coverage↓ -2.1

Immunitybio stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗